Press Releases

Pulmatrix, Inc. (NASDAQ: PULM) announces today that Dr. Robert Clarke has stepped down as Chief Executive Officer. Ted Raad will immediately transition from his current role as Chief Business...

Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone in the first quarter with the FDA providing approval to begin our planned Pulmazole Phase 2...

Pulmatrix, Inc. (NASDAQ: PULM; hereafter referred to as "Pulmatrix"), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the closing of its previously announced underwritten public offering of an aggregate of 1,719,554...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of its previously announced underwritten public offering of an aggregate of 10,666,666...

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in respiratory disease, announced today its entry...

Pulmatrix, Inc. (NASDAQ: PULM) announced today that members of its management team will present/participate in investor meetings at the following upcoming conferences: Oppenheimer's 29th Annual...

Pulmatrix, Inc. (NASDAQ: PULM) announced today that it received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, stating that the Company has regained...

Pulmatrix, Inc. (NASDAQ: PULM) today announces 2018 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. "The funds...

Pulmatrix, Inc. (NASDAQ: PULM) has been awarded five new patents that expand the intellectual property protection for Pulmatrix's PUR1800 and PUR5700 programs. These patents expand the...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with certain institutional investors,...

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in respiratory disease, announced today that the US...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the termination of its previously planned underwritten public offering, with Oppenheimer & Co.,...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced a 1-for-10 reverse split of its common stock, effective as of 5:00 pm Eastern Time, February 5,...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the closing and funding of its previously announced underwritten public offering of 5,323,530...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the closing and funding of its previously announced underwritten public offering of 1,561,177...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of 5,323,530 shares of its common stock at a price...

LEXINGTON, Mass., Jan. 30, 2019 /PRNewswire/ – Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it intends to offer and sell, subject to...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of 1,561,177 shares of its common stock at a price...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common...

Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with an institutional investor, providing...

Pulmatrix, Inc. (NASDAQ: PULM) announced the results of the completed first-in-human study of Pulmazole (PUR1900) — an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the...

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently...

Pulmatrix, Inc. (NASDAQ: PULM) today reported its third quarter results. "We remain focused on advancing the clinical development of our Pulmazole program," said Robert W. Clarke, Ph.D., chief...

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present preclinical data on the...